Santé Canada Health Canada

Biologic and Radiopharmaceutical Drugs Directorate

Drug Submission Performance Quarterly Report

January - March

2021

Canada

Health Canada is the federal department responsible for helping the people of Canada maintain and improve their health. Health Canada is committed to improving the lives of all of Canada's people and to making this country's population among the healthiest in the world as measured by longevity, lifestyle and effective use of the public health care system.

Également disponible en français sous le titre :
Direction des médicaments biologiques et radiopharmaceutiques - Rapport trimestriel du rendement des présentations de drogue - janvier - mars 2021

To obtain additional information, please contact:

Health Canada
Address Locator 0900C2
Ottawa, Ontario K1A 0K9
Tel.: 613-957-2991
Toll free: 1-866-225-0709
Fax: 613-941-5366
TTY: 1-800-465-7735
E-mail: hc.publications-publications.sc@canada.ca

© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health, 2021

Publication date: July 2021

This publication may be reproduced for personal or internal use only without permission provided the source is fully acknowledged.

Cat H162-5E-PDF
ISSN 2563-6723
Pub 210101

Table of Contents

OVERVIEW **6**

ACRONYMS **10**

Submission Types 10

Documents 12

FEE CATEGORIES **14**

NDS AND SNDS **16**

SUBMISSIONS RECEIVED **17**

NDS: Received by Fee Category 17

SNDS: Received by Fee Category 17

WORKLOAD **18**

NDS: Review Workload 18

SNDS: Review Workload 18

NDS: Review Workload by Fee Category 19

SNDS: Review Workload by Fee Category 19

APPROVALS **20**

NDS: Number Approved by Fee Category and NOC Type 20

SNDS: Number Approved by Fee Category and NOC Type 20

BIOSIMILARS: NDS & SNDS Market Authorizations **21**

Biosimilars: Number of Market Authorization for NDS & SNDS by Quarter 21

Biosimilars: NDS Market Authorizations during FY 2020-21 (Apr 1 - Mar 31 2021) 22

Biosimilars: SNDS Market Authorizations during FY 2020-21 (Apr 1 - Mar 31 2021) 23

REVIEW PERFORMANCE **24**

NDS: Review Decisions by Type 24

NDS: Review Cycle Completions 24

SNDS: Review Decisions by Type 25

SNDS: Review Cycle Completions 25

SCREENING PERFORMANCE **26**

NDS: Screening Decisions by Type 26

NDS: Screening Cycle Completions 26

SNDS: Screening Decisions by Type 27

SNDS: Screening Cycle Completions 27

REQUEST FOR PRIORITY REVIEW STATUS (NDS & SNDS)....28

Request for Priority Review Status: Number Received 28

Request for Priority Review Status: Decisions Rendered 29

Request for Priority Review Status: Performance 29

COV19 & COV19A....30

SUBMISSIONS RECEIVED....31

COV19 & COV19A: Number Received 31

WORKLOAD....31

COV19: Review Workload 31

AUTHORIZATIONS....32

COV19 & COV19A: Number Authorized 32

NC: NOTIFIABLE CHANGE....33

NC: Number Received by Class 34

WORKLOAD....35

NC-SAFETY: Review Workload 35

NC-QUALITY: Review Workload 35

NC-SAFETY: Review Workload by Class 36

NC-QUALITY: Review Workload by Class 36

PERFORMANCE....37

NC: Review Completions by Class 37

NC: Screening Completions by Class 37

NC: Decision Documents by Class 38

ADMINISTRATIVE SUBMISSIONS....39

ADMINISTRATIVE SUBMISSIONS (Processed by BRDD)....39

Administrative Submissions (with BRDD Review): Number Received 39

Administrative Submissions (with BRDD Review): Number Approved 39

CLINICAL TRIAL APPLICATIONS (CTA)....41

CTA: Number Received by Phase 41

CTA: Number of Decisions by Document Type 42

CTA: Review Completed with a 30 Day Target 42

CLINICAL TRIAL APPLICATION- AMENDMENTS (CTA-A) 43

CTA-A: Number Received by Phase 43

CTA-A: Decisions by Type 44

CTA-A: Reviews Completed with a 30 Day Target 44

CTA & CTA-A RECEIVED UNDER THE INTERIM ORDER COVID-19 45

CTA: Number Received under the Interim Order Covid-19 by phase 45

CTA-A: Number Received under the Interim Order Covid-19 by phase 45

DINB: APPLICATION FOR A DRUG IDENTIFICATION NUMBER - BIOLOGICAL PRODUCT 46

DINB: Number Received by Fee Category 46

REVIEW WORKLOAD 47

DINB: Review Workload 47

DINB: Review Workload by Fee Category 47

SCREENING WORKLOAD 48

DINB: Screening Workload 48

DINB: Screening Workload by Fee Category 48

DECISIONS 49

DINB: Number of Decisions by Fee Category 49

PERFORMANCE 50

DINB: Review Cycle Completions 50

DINB: Screening Cycle Completions 50

POST-AUTHORIZATION DIVISION 1 CHANGE FOR A BIOLOGIC DRUG PRODUCT (PDC-B) 51

PDC-B: Number Received 51

YEARLY BIOLOGIC PRODUCT REPORTS (YBPR) 52

YBPR: Number Received 52

APPENDIX A: PRE-SUBMISSION MEETINGS 53

Pre-submission Meetings Held / Feedback Provided 53

OVERVIEW

The Biologic and Radiopharmaceutical Drugs Directorate (BRDD) Quarterly Drug Submission Performance Report reflects biologic and radiopharmaceutical drug submission review activity over five consecutive quarters: from January - March 2020 to January - March 2021. Statistics are provided by Submission Type and show the number received, the number in workload, the number of decisions and the number of approvals.

Several significant events occurred during the spring of 2020 including the COVID-19 Pandemic and the implementation of revised fees in accordance with the *Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)*.

- Health Canada employees shifted from working in their offices to working remotely from home. Fortunately in 2019, HPFB had implemented new forms to take advantage of the gateway for transmission of regulatory transactions in electronic format. [1] This method is more efficient than sending transactions on physical media by courier and is mandatory as of October 1, 2020.

- The publication of the Quarterly Drug Submission Performance Report was cancelled for two quarters (there were no reports published for Q4 Jan-Mar 2020 and Q1 Apr-June 2020), however figures for the past three quarters are provided in this report.

- An Interim Order Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19 was approved and on August 13, 2020 the Minister of Health approved an order to temporarily extend the default period to review clinical trial applications and amendments from 30 days to 45 days to allow Health Canada to expedite the influx of COVID-19 related clinical trial applications. The number of CTA and CTA-As received under orders are included in this report.

- The Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 (ISAD Interim Order) was approved by the Governor in Council on September 25, 2020. This interim order was introduced, in part, to create a new authorization pathway to help expedite the authorization of drugs and vaccines for COVID-19. The number of applications and amendments filed, the number of applications and amendments in review, and the number of authorizations issued under the ISAD Interim Order are included in this report.

[1] The Regulatory Enrolment Process (REP) and the Common Electronic Submissions Gateway (CESG)

- There was a significant increase in the volume of Drug Identification Number Applications for Disinfectant products (DIND) received (see the Quarterly Drug Submission Performance Report for the Natural and Non-Prescription Health Products Directorate (NNHPD)).

- On April 1, 2020, revised fees were implemented in accordance with the *Fees in Respect of Drugs and Medical Devices Order (SOR/2019-124)*. In addition, submissions based only on clinical or non-clinical data, in support of safety updates to the labelling materials for a new drug are now submitted as an SNDS or SANDS (and not as an NC).

General Information

There are several steps involved in the drug submission review[2] and approval process:

- administrative processing,
- regulatory and scientific screening and
- in-depth scientific review.

When deficiencies or non-compliance issues are found, a company may submit responses before a final decision can be reached and thus multiple review cycles may be required. A submission's approval time can vary depending on the number and type of review cycles needed.

Submissions Received are counts of submissions received during the year using the filing date (CR date) which is the date the submission is considered administratively complete by Health Canada.

Workload is the number of submissions "under active review" on the last day of the quarter. **"Backlog"** is the proportion of the workload that is over target. Often the term workload is used to mean the amount of work received over a period of time and is a common source of confusion.

Approvals[3] are Notice of Compliances (NOC) Issued or Issuable. An NOC issuable is when a submission's NOC is placed "on hold" awaiting authorization to market, due to Patented Medicines (NOC) Regulations or due to changes from Prescription to Non-Prescription.

Authorization means an authorization issued under section 5 of the ISAD Interim Order.

A **review cycle completion**[4] is counted upon the conclusion of an in-depth scientific review that then results in a decision of approval or non-approval. The time taken to complete a cycle (excluding any pause days[5]) is compared to a set performance standard which is based on the type of submission, class and cycle (status).

Performance for all submissions or applications filed after April 1, 2020 is tracked individually.

[2] For further clarification refer to the Guidance for Industry: Management of Drug Submissions.

[3] Final results from confirmatory trials submitted in the form of an SNDS-C are included in the SNDS Received, Workload and Performance figures. SNDS-C are not included in the SNDS Approval figures. For further Clarification refer to the Guidance Document: Notice of Compliance with Conditions (NOC/c).

[4] Review cycles include all types e.g. Review 1, Review 2, Review QN. The total number of "review decisions" may surpass the total number of review cycle completions as they include cancellations/withdrawals that occur while the submission is 'inactive'. For example, a withdrawal can be issued when a company fails to respond to a notice of non-compliance within the allotted time frame. A 'Cancelled by Company' is counted as a review decision when a company sends a cancellation letter after the submission's original materials have been accepted for review.

[5] In the event that the review clock has been paused, the duration of the pause will be deducted from the total review time when calculating performance. That is, the days during which the clock is paused will not count when measuring performance (effective date: April 1, 2020).

"First Cycle Review" Approvals are those submissions approved without having to go through several review cycles to resolve submission deficiencies or non-compliance issues, and exclude "refiled"[6] submissions.

Biosimilar is a biologic drug that enters the market subsequent to a version previously authorized in Canada, and with demonstrated similarity to a reference biologic drug. Biosimilar relies in part on prior information regarding safety and efficacy that is deemed relevant due to the demonstration of similarity to the reference biologic drug and which influences the amount and type of original data required.

Any questions or comments on this report should be forwarded to:

Office of Submissions and Intellectual Property, Resource Management and Operations Directorate
Finance Building, A.L. # 0202A1
101 Tunney's Pasture Driveway, Tunney's Pasture
Ottawa, Ontario, K1A 0K9

Tel: (613) 941-7281 Fax: (613) 941-0825

Email: hc.osip-bppi.sc@canada.ca

[6] For further clarification refer to the Guidance for Industry: Management of Drug Submissions.

ACRONYMS

Submission Types

ANDS	-	Abbreviated New Drug Submission
COV19	-	Application under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19
COV19A	-	Application for an amendment to an application under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19
CTA	-	Clinical Trial Application
CTA-A	-	Clinical Trial Application - Amendment
DINA	-	Application for a Drug Identification Number for a pharmaceutical product, including non-prescription products attesting to a Labelling Standard
DINB	-	Application for a Drug Identification Number for a biological product
DIND	-	Application for a Drug Identification Number for a disinfectant product
DINF	-	Application for a Drug Identification Number for a Category IV Monograph Product
EUANDS	-	Abbreviated Extraordinary Use New Drug Submission
EUNDS	-	Extraordinary Use New Drug Submission
EUSANDS	-	Supplement to an Abbreviated Extraordinary Use New Drug Submission
EUSNDS	-	Supplement to an Extraordinary Use New Drug Submission
MPNDS	-	Pre-Submission Meeting New Drug Submission
MPSNDS	-	Pre-Submission Meeting Supplement to a New Drug Submission
NC	-	Notifiable Change
NDS	-	New Drug Submission
NDS-D	-	New Drug Submission for Disinfectant products
PDC	-	Post-authorization Division 1 Change for a pharmaceutical product
PDC-B	-	Post-authorization Division 1 Change for a biologic drug product
PRNDS	-	Request for Priority Review Status: New Drug Submission
PRSNDS	-	Request for Priority Review Status: Supplemental New Drug Submission

SANDS	-	Supplement to an Abbreviated New Drug Submission
SANDS-C	-	Supplement to an Abbreviated New Drug Submission - Confirmatory
SNDS	-	Supplement to a New Drug Submission
SNDS-C	-	Supplement to a New Drug Submission - Confirmatory
SNDS-D	-	Supplement to a New Drug Submission for Disinfectant products
YBPR	-	Yearly Biologic Product Report

Documents

NOC	-	Notice of Compliance
NOC-c	-	Notice of Compliance with Conditions
IO_NOA		Notice of Authorization
IO_NOA_TC		Notice of Authorization with Terms and Conditions
Issuable NOC (Patent)	-	NOC on Hold due to Patented Medicines (NOC) Regulations
Issuable NOC (Rx to OTC)	-	NOC on Hold due to changes (Prescription to Non-Prescription)
NON	-	Notice of Non-Compliance
NOD	-	Notice of Deficiency
NON Withdrawal	-	Notice of Non-Compliance Withdrawal Letter
NOD Withdrawal	-	Notice of Deficiency Withdrawal Letter

This page is left blank intentionally.

Fee Categories

Fee Category	Description
New active substance	Submissions in support of a drug, other than a disinfectant, that contains a medicinal ingredient not previously approved in a drug in Canada and that is not a variation of a previously approved medicinal ingredient such as a salt, ester, enantiomer, solvate or polymorph
Clinical or non-clinical data and chemistry and manufacturing data	Submissions based on clinical or non-clinical data and chemistry and manufacturing data for a drug that does not include a new active substance
Clinical or nonclinical data only	Submissions based only on clinical or non-clinical data for a drug that does not include a new active substance
Comparative studies	Submissions based on comparative studies (e.g., clinical or non-clinical data, bioavailability data and data on the pharmacokinetics and pharmacodynamics of the drug) with or without chemistry and manufacturing data for a drug that does not include a new active substance
Chemistry and manufacturing data only	Submissions based only on chemistry and manufacturing data for a drug that does not include a new active substance
Clinical or nonclinical data only, in support of safety updates to the labelling	Submissions based only on clinical or non-clinical data, in support of safety updates to the labelling materials for a new drug that does not include a new active substance
Switch status from prescription drug to non-prescription drug	Submissions based only on data that support the modification or removing of a medicinal ingredient listed in Schedule F of the Food and Drug Regulations (i.e. identical claim for existing drug) - Category discontinued
Labelling only	Submissions, other than those described in item 9, 12 or 13, of labelling material, that include data in support of the following: brand name assessment, standardized or published test methods, in vitro or in vivo photostability or applications for a drug identification number in support of changes to brand names of non-prescription drugs (but not including examination of other supporting clinical or non-clinical data, comparative data, or chemistry and manufacturing data)

Fee Category	Description
Labelling only (generic drugs)	Submissions in support of a change to the labelling to be consistent with the Canadian reference product that do not include any additional labelling updates requiring a labelling assessment
Administrative submission	Submissions in support of a change in the manufacturer's name or brand name, including the following: changes in ownership of the drug, request for an additional brand name or changes resulting from a licensing agreement being entered into by two manufacturers that do not require an assessment of labelling material or brand name (e.g., post-authorization label changes filed by licensees to remain identical to licensor's drug and post-authorization chemistry and manufacturing updates for drugs listed in Schedule C or D of the Food and Drugs Act)
Disinfectant – full review	Submissions, other than those described in item 12, that include data in support of a disinfectant
Labelling only (disinfectants)	Submissions in support of changes to the labelling of disinfectants that do not require supporting data, submissions in support of safety updates for disinfectants that are new drugs or submissions in support of a change in the manufacture's name or brand name that requires a review of labelling material due to deviations from the previously authorized labelling or drug
Drug identification number application - labelling standards	Applications, including those that pertain to changes to brand names for non-prescription drugs, that include an attestation of compliance with a labelling standard or Category IV Monograph for a drug that does not include clinical or non-clinical data or chemistry and manufacturing data
Published data only	Submissions based only on published clinical or non-clinical data for a drug that does not include a new active substance - Category discontinued

For further information please consult the Guidance Document: Fees for the Review of Human and Disinfectant Drug Submissions and Applications.

New Drug Submissions (NDS)

&

Supplemental New Drug Submissions (SNDS)

SUBMISSIONS RECEIVED [7]

NDS: Received by Fee Category



	Jan-Mar 2020	Apr-Jun 2020	Jul-Sep 2020	Oct-Dec 2020	Jan-Mar 2021
Labelling Only	0	0	14	3	1
Clinical or Non-Clin and C&M	7	2	4	6	4
Comparative Studies	0	0	0	0	0
New Active Substance	5	1	2	9	6
Total	12	3	20	19	11
Priority Class	1	1	1	1	1
NOC-C Class	0	0	1	1	1
Extraordinary Use NDS	0	0	0	0	0
Biosimilar	3	1	2	4	3

Quarter

SNDS: Received by Fee Category



	Jan-Mar 2020	Apr-Jun 2020	Jul-Sep 2020	Oct-Dec 2020	Jan-Mar 2021
Safety Update Label	0	7	17	26	22
Labelling Only	8	7	10	8	8
Chemistry & Manufacturing	12	17	27	21	10
Clinical or Non-Clin and C&M	2	2	2	2	2
Published Data Only	0	0	0	0	0
Clinical or Non-Clin Only	26	24	24	27	14
Comparative Studies	0	0	0	0	2
Total	48	57	80	84	58
Priority Class	0	1	0	1	1
NOC-C Class	1	1	0	0	0
SNDS - Confirmatory	5	0	2	2	2
Biosimilar	3	3	9	7	4
Extraordinary Use SNDS	2	0	0	0	0

Quarter

[7] Submissions granted Priority Review Status or found eligible for advance NOC/c consideration are assigned a shortened review target to account for the Priority nature of the submission. For further clarification, please see the Priority Review of Drug Submissions Policy , the Notice of Compliance with conditions (NOC/c) Guidance and the Management of Drug Submissions Guidance.

WORKLOAD

NDS: Review Workload



SNDS: Review Workload



WORKLOAD

NDS: Review Workload by Fee Category

NDS: REVIEW WORKLOAD BY FEE CATEGORY (excluding Administrative) and End of Quarter					
FEE Category	2020-03-31	2020-06-30	2020-09-30	2020-12-31	2021-03-31
Clinical or Non-Clin and C&M	17	22	19	14	14
Backlog	*0*	*0*	*1*	*0*	*0*
New Active Substance	12	10	9	13	14
Backlog	*0*	*0*	*0*	*0*	*0*
Labelling Only	0	0	7	11	4
Backlog	*0*	*0*	*0*	*0*	*0*
Total	29	32	35	38	32
Non Backlog	29	32	34	38	32
Backlog	0	0	1	0	0
% in Backlog	0%	0%	3%	0%	0%
Priority (subset)	2	2	1	2	3
Backlog	*0*	*0*	*0*	*0*	*0*

SNDS: Review Workload by Fee Category

SNDS: REVIEW WORKLOAD BY FEE CATEGORY (excluding Administrative) and End of Quarter					
FEE Category	2020-03-31	2020-06-30	2020-09-30	2020-12-31	2021-03-31
Comparative Studies	0	0	0	0	2
Backlog	*0*	*0*	*0*	*0*	*0*
Chemistry & Manufacturing	31	28	26	26	31
Backlog	*0*	*0*	*0*	*0*	*0*
Clinical or Non-Clin Only	63	70	75	78	75
Backlog	*0*	*0*	*0*	*0*	*0*
Clinical or Non-Clin and C&M	8	8	8	6	5
Backlog	*0*	*0*	*0*	*0*	*0*
Published Data	3	2	0	0	0
Backlog	*0*	*0*	*0*	*0*	*0*
Labelling Only	4	2	5	8	13
Backlog	*0*	*0*	*0*	*0*	*0*
Safety Update Label	0	4	17	28	25
Backlog	*0*	*0*	*0*	*1*	*1*
Total	109	114	131	146	151
Non Backlog	109	114	131	145	150
Backlog	0	0	0	1	1
% in Backlog	0%	0%	0%	1%	1%
Priority (subset)	0	1	1	1	2
Backlog	*0*	*0*	*0*	*0*	*0*
SNDS-C (Confirmatory)	6	4	4	5	5
Backlog	*0*	*0*	*0*	*0*	*0*

APPROVALS [8]

NDS: Number Approved by Fee Category and NOC Type



	Jan-Mar 2020	Apr-Jun 2020	Jul-Sep 2020	Oct-Dec 2020	Jan-Mar 2021
Comparative Studies	0	0	0	0	0
Labelling Only	0	0	0	5	9
Clinical or Non-Clin and C&M	6	2	2	8	7
New Active Substance	2	3	4	3	2
Total	8	5	6	16	18
Notice of Compliance	6	5	3	15	18
NOC with Conditions	0	0	1	1	0
NOC on Hold (Patent)	2	0	2	0	0
Priority Class	1	1	1	1	0
NOC-C Class	0	0	1	0	0
Biosimilar	5	1	2	5	2

SNDS: Number Approved by Fee Category and NOC Type



	Jan-Mar 2020	Apr-Jun 2020	Jul-Sep 2020	Oct-Dec 2020	Jan-Mar 2021
Safety Update Label	0	0	3	8	25
Labelling Only	4	6	2	4	6
Comparative Studies	0	0	0	0	0
Chemistry & Manufacturing	7	21	21	18	14
Clinical or Non-Clin and C&M	3	2	2	4	2
Published Data Only	2	0	2	0	0
Clinical or Non-Clin Only	11	13	16	25	19
Total	27	42	46	59	66
Notice of Compliance	26	40	45	55	63
NOC with Conditions	0	0	0	1	2
NOC on Hold (Patent)	1	2	1	3	1
Priority Class	0	0	0	1	0
NOC-C Class	0	0	0	1	1
Biosimilar	2	3	3	6	7

[8] Submissions granted Priority Review Status or found eligible for advance NOC/c consideration are assigned a shortened review target to account for the Priority nature of the submission. For further clarification, please see the Priority Review of Drug Submissions Policy , the Notice of Compliance with conditions (NOC/c) Guidance and the Management of Drug Submissions Guidance.

BIOSIMILARS: NDS & SNDS Market Authorizations

Biosimilars: Number of Market Authorization for NDS & SNDS by Quarter

Submission Type	Class	Jan-Mar 2020	Apr-Jun 2020	Jul-Sep 2020	Oct-Dec 2020	Jan-Mar 2021
NDS	CLIN/C&M	3	4	0	9	3
NDS Total		**3**	**4**	**0**	**9**	**3**
SNDS	C&M ONLY	0	1	0	3	4
	C&M/LABELLING	0	0	1	2	0
	CLIN ONLY	1	2	1	3	1
	CLIN/C&M	0	0	0	0	1
	COMP/C&M	0	0	0	0	0
	LABELLING ONLY	0	0	0	1	0
	SAFETY UPDATE LABEL	0	0	0	1	1
SNDS Total		**1**	**3**	**2**	**10**	**7**

Biosimilars: NDS Market Authorizations during FY 2020-21 (Apr 1 - Mar 31 2021)

Brand Name	Class	Company	Active Ingredient(s)	Quarter FY 2020-21	Notice of Compliance (NOC) Date
ADALIMUMAB INJECTION	CLIN/C&M	PFIZER CANADA ULC	ADALIMUMAB	Q4	2021-Jan-14
AMGEVITA	CLIN/C&M	AMGEN CANADA INC.	ADALIMUMAB	Q3	2020-Nov-04
HULIO	CLIN/C&M	BGP PHARMA ULC	ADALIMUMAB	Q3	2020-Nov-24
HYRIMOZ	CLIN/C&M	SANDOZ CANADA INCORPORATED	ADALIMUMAB	Q3	2020-Nov-04
IDACIO	CLIN/C&M	FRESENIUS KABI CANADA LTD.	ADALIMUMAB	Q3	2020-Oct-30
INCLUNOX, INCLUNOX HP	CLIN/C&M	SANDOZ CANADA INCORPORATED	ENOXAPARIN SODIUM	Q3	2020-Nov-05
NIVESTYM	CLIN/C&M	PFIZER CANADA ULC	FILGRASTIM (R-METHUG-CSF)	Q1	2020-Apr-16
NOROMBY, NOROMBY HP	CLIN/C&M	JUNO PHARMACEUTICALS CORP.	ENOXAPARIN SODIUM	Q3	2020-Oct-14
NYVEPRIA	CLIN/C&M	PFIZER CANADA ULC	PEGFILGRASTIM	Q3	2020-Oct-28
REDESCA / REDESCA HP	CLIN/C&M	SHENZHEN TECHDOW PHARMACEUTICAL CO. LTD.	ENOXAPARIN SODIUM	Q3	2020-Dec-07
RIABNI	CLIN/C&M	AMGEN CANADA INC.	RITUXIMAB	Q4	2021-Mar-11
RIXIMYO	CLIN/C&M	SANDOZ CANADA INCORPORATED	RITUXIMAB	Q1	2020-Apr-28
RUXIENCE	CLIN/C&M	PFIZER CANADA ULC	RITUXIMAB	Q1	2020-May-04
TRURAPI	CLIN/C&M	SANOFI-AVENTIS CANADA INC	INSULIN ASPART	Q3	2020-Oct-15
ZIEXTENZO	CLIN/C&M	SANDOZ CANADA INCORPORATED	PEGFILGRASTIM	Q1	2020-Apr-21
ZIRABEV	CLIN/C&M	PFIZER CANADA ULC	BEVACIZUMAB	Q4	2021-Jan-05
New Drug Submission Total					**16**

Biosimilars: SNDS Market Authorizations during FY 2020-21 (Apr 1 - Mar 31 2021)

Brand Name	Class	Company	Active Ingredient(s)	Quarter FY 2020-21	Notice of Compliance (NOC) Date
AMGEVITA	C&M ONLY	AMGEN CANADA INC.	ADALIMUMAB	Q3	2020-Nov-04
AMGEVITA	C&M ONLY	AMGEN CANADA INC.	ADALIMUMAB	Q3	2020-Nov-04
AMGEVITA	CLIN ONLY	AMGEN CANADA INC.	ADALIMUMAB	Q3	2020-Nov-04
AMGEVITA	CLIN ONLY	AMGEN CANADA INC.	ADALIMUMAB	Q3	2020-Nov-04
AMGEVITA	LABELLING ONLY	AMGEN CANADA INC.	ADALIMUMAB	Q3	2020-Nov-04
BASAGLAR	C&M ONLY	ELI LILLY CANADA INC.	INSULIN GLARGINE	Q4	2021-Jan-20
BASAGLAR	SAFETY UPDATE LABEL	ELI LILLY CANADA INC.	INSULIN GLARGINE	Q4	2021-Mar-26
BRENZYS (PFS), BRENZYS (AUTOINJECTOR)	CLIN ONLY	SAMSUNG BIOEPIS CO., LTD	ETANERCEPT	Q2	2020-Aug-19
ERELZI (PEN), ERELZI (SYRINGE)	CLIN ONLY	SANDOZ CANADA INCORPORATED	ETANERCEPT	Q1	2020-Jun-09
FULPHILA	C&M ONLY	BGP PHARMA ULC	PEGFILGRASTIM	Q1	2020-May-15
HADLIMA, HADLIMA PUSH TOUCH	C&M/LABELLING	SAMSUNG BIOEPIS CO., LTD	ADALIMUMAB	Q2	2020-Jul-15
HADLIMA, HADLIMA PUSHTOUCH	CLIN ONLY	SAMSUNG BIOEPIS CO., LTD	ADALIMUMAB	Q3	2020-Nov-26
HERZUMA	C&M LABELLING	CELLTRION HEALTHCARE CO. LTD.	TRASTUZUMAB	Q3	2020-Oct-21
HYRIMOZ	C&M LABELLING	SANDOZ CANADA INCORPORATED	ADALIMUMAB	Q3	2020-Nov-04
INFLECTRA	C&M ONLY	CELLTRION HEALTHCARE CO LTD.	INFLIXIMAB	Q4	2021-Feb-19
KANJINTI	C&M ONLY	AMGEN CANADA INC.	TRASTUZUMAB	Q3	2020-Nov-17
LAPELGA	SAFETY UPDATE LABEL	APOTEX INC.	PEGFILGRASTIM	Q3	2020-Dec-17
MVASI	CLIN ONLY	AMGEN CANADA INC.	BEVACIZUMAB	Q4	2021-Jan-05
REMSIMA SC, REMSIMA/REMSIMA SC	CLIN/C&M	CELLTRION HEALTHCARE CO LTD.	INFLIXIMAB	Q4	2021-Jan-28
TRAZIMERA	C&M ONLY	PFIZER CANADA ULC	TRAZIMERA	Q4	2021-Mar-12
TRUXIMA	CLIN ONLY	CELLTRION HEALTHCARE CO LTD	RITUXIMAB	Q1	2020-May-22
ZIEXTENZO	C&M ONLY	SANDOZ CANADA INCORPORATED	PEGFILGRASTIM	Q4	2021-Mar-22
Supplemental New Drug Submission Total					**22**

Please note: Approved Biosimilars that remain on Intellectual Property Hold are not included.

Biosimilar: A biologic drug that enters the market subsequent to a version previously authorized in Canada, and with demonstrated similarity to a reference biologic drug. Biosimilar relies in part on prior information regarding safety and efficacy that is deemed relevant due to the demonstration of similarity to the reference biologic drug and which influences the amount and type of original data required.

REVIEW PERFORMANCE

NDS: Review Decisions by Type



NDS: Review Cycle Completions



REVIEW PERFORMANCE

SNDS: Review Decisions by Type



SNDS: Review Cycle Completions



SCREENING PERFORMANCE

NDS: Screening Decisions by Type



NDS: Screening Cycle Completions



SCREENING PERFORMANCE

SNDS: Screening Decisions by Type



SNDS: Screening Cycle Completions



REQUEST FOR PRIORITY REVIEW STATUS (NDS & SNDS)

Request for Priority Review Status: Number Received



	Jan-Mar 2020	Apr-Jun 2020	Jul-Sep 2020	Oct-Dec 2020	Jan-Mar 2021
PR-NDS NAS	0	0	0	0	0
PR-SNDS CLIN/C&M	0	0	0	0	0
PR-NDS CLIN/C&M	1	0	0	0	0
PR-NDS CLIN ONLY	0	1	1	2	2
PR-SNDS C&M	0	0	0	0	0
PR-SNDS CLIN ONLY	0	1	1	2	1
Total	1	2	2	4	3

Request for Priority Review Status: Decisions Rendered



Request for Priority Review Status: Performance



Application under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 (COV19)

&

Application for an amendment to an application under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 (COV19A)

SUBMISSIONS RECEIVED

COV19 & COV19A: Number Received



WORKLOAD

COV19: Review Workload



AUTHORIZATIONS

COV19 & COV19A: Number Authorized



NC: NOTIFIABLE CHANGE

NC: NOTIFIABLE CHANGE

NC: Number Received by Class



	Jan-Mar 2020	Apr-Jun 2020	Jul-Sep 2020	Oct-Dec 2020	Jan-Mar 2021
Safety (90)	34	2	0	1	1
Safety (120)	4	0	0	0	0
Quality (90)	110	149	152	137	125
Total	148	151	152	138	126

WORKLOAD

NC-SAFETY: Review Workload



NC-QUALITY: Review Workload



WORKLOAD

NC-SAFETY: Review Workload by Class

BRDD NC - SAFETY: REVIEW WORKLOAD AT END OF QUARTER					
Class	2020-03-31	2020-06-30	2020-09-30	2020-12-31	2021-03-31
SAFETY - 90 day	24	2	0	0	0
Backlog	0	0	0	0	0
SAFETY - 120 day	3	1	0	0	0
Backlog	0	0	0	0	0
Total	27	3	0	0	0
Non Backlog	27	3	0	0	0
BACKLOG	0	0	0	0	0
% in Backlog	0%	0%	0%	0%	0%

NC-QUALITY: Review Workload by Class

BRDD NC - QUALITY: REVIEW WORKLOAD AT END OF QUARTER					
CLASS	2020-03-31	2020-06-30	2020-09-30	2020-12-31	2021-03-31
QUALITY - 90 day	67	98	98	97	91
Backlog	1	0	0	0	0
Total	67	98	98	97	91
Non Backlog	66	98	98	97	91
BACKLOG	1	0	0	0	0
% in Backlog	1%	0%	0%	0%	0%

PERFORMANCE

NC: Review Completions by Class



NC: Screening Completions by Class



NC: Decision Documents by Class

NC - SAFETY (90)					
DOCUMENT TYPE	**Jan-Mar 2020**	**Apr-Jun 2020**	**Jul-Sep 2020**	**Oct-Dec 2020**	**Jan-Mar 2021**
NO OBJECTION LETTER	16	26	2	0	0
REJECTION LETTER (SCR)	0	2	0	0	0
CANCELLED BY COMPANY	4	2	0	1	1
SCREENING DEFICIENCY NOTICE	0	0	0	0	0
NOT SATISFACTORY NOTICE	0	0	0	0	0
NC - HOLD (PATENT)	0	0	0	0	0

NC - QUALITY (90)					
DOCUMENT TYPE	**Jan-Mar 2020**	**Apr-Jun 2020**	**Jul-Sep 2020**	**Oct-Dec 2020**	**Jan-Mar 2021**
NO OBJECTION LETTER	100	121	129	133	133
NOT SATISFACTORY NOTICE	0	0	0	0	0
REJECTION LETTER (SCR)	0	0	0	1	0
SCREENING DEFICIENCY NOTICE	0	0	0	0	0
CANCELLED BY COMPANY	3	4	3	12	4
NC - HOLD (PATENT)	0	0	0	0	0

NC - SAFETY (120)					
DOCUMENT TYPE	**Jan-Mar 2020**	**Apr-Jun 2020**	**Jul-Sep 2020**	**Oct-Dec 2020**	**Jan-Mar 2021**
NO OBJECTION LETTER	1	2	1	0	0
NOT SATISFACTORY NOTICE	0	0	0	0	0
REJECTION LETTER (SCR)	0	0	0	0	0
SCREENING DEFICIENCY NOTICE	0	0	0	0	0
CANCELLED BY COMPANY	1	0	0	0	0

NC - ADMINISTRATIVE					
DOCUMENT TYPE	**Jan-Mar 2020**	**Apr-Jun 2020**	**Jul-Sep 2020**	**Oct-Dec 2020**	**Jan-Mar 2021**
NO OBJECTION LETTER	0	0	0	0	0
CANCELLED BY COMPANY	0	0	0	0	0

ADMINISTRATIVE SUBMISSIONS (Processed by BRDD)

(e.g. product name changes that require a drug name review)

Administrative Submissions (with BRDD Review): Number Received



	Jan-Mar 2020	Apr-Jun 2020	Jul-Sep 2020	Oct-Dec 2020	Jan-Mar 2021
DINB Administrative	0	1	0	0	2
NC Administrative	0	0	0	0	0
NDS Administrative	2	3	3	2	2
SNDS Administrative	0	0	0	0	0
TOTAL	2	4	3	2	4

Administrative Submissions (with BRDD Review): Number Approved



	Jan-Mar 2020	Apr-Jun 2020	Jul-Sep 2020	Oct-Dec 2020	Jan-Mar 2021
NDS - ADMINISTRATIVE	1	1	4	1	4
SNDS - ADMINISTRATIVE	0	0	0	0	0
TOTAL	1	1	4	1	4

CLINICAL TRIAL APPLICATIONS AND AMENDMENTS

(CTA & CTA-A)

CLINICAL TRIAL APPLICATIONS (CTA)

CTA: Number Received by Phase



	Jan-Mar 2020	Apr-Jun 2020	Jul-Sep 2020	Oct-Dec 2020	Jan-Mar 2021
Phase 1 HEALTHY HUMAN	1	2	3	3	0
Phase 1 OTHER	15	6	13	11	16
Phase 1/2	3	12	6	12	8
Phase 2	21	20	32	27	34
Phase 2/3	1	6	5	2	5
Phase 3	40	33	29	50	36
Phase Other	9	6	3	13	15
Total	90	85	91	118	114

CTA: Number of Decisions by Document Type

CTA					
DOCUMENT TYPE	**Jan-Mar 2020**	**Apr-Jun 2020**	**Jul-Sep 2020**	**Oct-Dec 2020**	**Jan-Mar 2021**
NO OBJECTION LETTER	78	76	77	115	85
CANCELLED BY COMPANY DURING REVIEW	3	4	3	7	7
CANCELLED BY COMPANY AT PROCESSING	3	2	0	2	2
REJECTION LETTER (SCR)	0	0	0	1	0
NOT SATISFACTORY NOTICE	0	0	0	0	0
NOTICE OF AUTHORIZATION	0	2	2	7	3

CTA: Review Completed with a 30 Day Target



	Jan-Mar 2020	Apr-Jun 2020	Jul-Sep 2020	Oct-Dec 2020	Jan-Mar 2021
Target MET	81	82	115	97	95
Target Not Met	0	0	0	0	0
Total	81	82	115	97	95
Percent within target	100%	100%	100%	100%	100%
Average days	24	22	26	27	26
Median days	27	27	28	28	28

CLINICAL TRIAL APPLICATION- AMENDMENTS (CTA-A)

CTA-A: Number Received by Phase



	Jan-Mar 2020	Apr-Jun 2020	Jul-Sep 2020	Oct-Dec 2020	Jan-Mar 2021
Phase 1 HEALTHY HUMAN	1	2	3	2	4
Phase 1 OTHER	62	53	32	43	68
Phase 1/2	26	24	27	20	43
Phase 2	71	88	77	57	92
Phase 2/3	13	12	6	11	13
Phase 3	132	138	128	82	139
Phase Other	14	8	16	11	14
Total	319	325	289	226	373

CTA-A: Decisions by Type

CTA-A					
DOCUMENT TYPE	Jan-Mar 2020	Apr-Jun 2020	Jul-Sep 2020	Oct-Dec 2020	Jan-Mar 2021
NO OBJECTION LETTER	268	310	261	250	294
REJECTION LETTER (SCR)	10	3	4	5	2
CANCELLED BY COMPANY DURING REVIEW	2	1	3	1	7
CANCELLED BY COMPANY AT PROCESSING	5	3	1	3	2
NOTICE OF AUTHORIZATION	0	0	0	4	10

CTA-A: Reviews Completed with a 30 Day Target



CTA & CTA-A RECEIVED UNDER THE INTERIM ORDER COVID-19

CTA: Number Received under the Interim Order Covid-19 by phase



	Jan-Mar 2020	Apr-Jun 2020	Jul-Sep 2020	Oct-Dec 2020	Jan-Mar 2021
Phase 1 HEALTHY HUMAN	0	0	2	2	0
Phase 1 OTHER	0	0	0	0	1
Phase 1/2	0	0	0	2	1
Phase 2	0	0	1	1	3
Phase 2/3	0	1	1	1	3
Phase 3	0	1	0	2	1
Phase Other	0	0	0	1	0
Total	0	2	4	9	9

CTA-A: Number Received under the Interim Order Covid-19 by phase



	Jan-Mar 2020	Apr-Jun 2020	Jul-Sep 2020	Oct-Dec 2020	Jan-Mar 2021
Phase 1 HEALTHY HUMAN	0	0	0	0	2
Phase 1 OTHER	0	0	0	0	1
Phase 1/2	0	0	0	0	2
Phase 2	0	0	0	0	3
Phase 2/3	0	0	0	4	3
Phase 3	0	0	0	2	1
Phase Other	0	0	0	0	0
Total	0	0	0	6	12

These figures are a subset of the total CTA and CTA-A received.

DINB: APPLICATION FOR A DRUG IDENTIFICATION NUMBER - BIOLOGICAL PRODUCT

DINB: Number Received by Fee Category



	Jan-Mar 2020	Apr-Jun 2020	Jul-Sep 2020	Oct-Dec 2020	Jan-Mar 2021
Labelling Only	2	13	0	0	0
Chemistry & Manufacturing	0	0	2	0	1
Comparative Studies	0	0	0	0	0
Clinical or Non-Clin and C&M	0	0	0	0	0
Total	2	13	2	0	1

REVIEW WORKLOAD

DINB: Review Workload



DINB: Review Workload by Fee Category

DINB: REVIEW WORKLOAD BY FEE CATEGORY (excluding Administrative) and End of Quarter					
FEE Category	2020-03-31	2020-06-30	2020-09-30	2020-12-31	2021-03-31
Labelling Only	3	2	15	0	1
Backlog	*0*	*0*	*0*	*0*	*0*
Chemistry & Manufacturing	1	1	2	2	2
Backlog	*0*	*0*	*0*	*0*	*0*
Total	4	3	17	2	3
Non Backlog	4	3	17	2	3
Backlog	0	0	0	0	0
% in Backlog	0%	0%	0%	0%	0%

SCREENING WORKLOAD

DINB: Screening Workload



DINB: Screening Workload by Fee Category

DINB: SCREENING WORKLOAD BY FEE CATEGORY (excluding Administrative) and End of Quarter					
FEE Category	2020-03-31	2020-06-30	2020-09-30	2020-12-31	2021-03-31
Labelling Only	2	13	0	0	0
Backlog	*0*	*0*	*0*	*0*	*0*
Clinical or Non-Clin and C&M	0	0	0	0	0
Backlog	*0*	*0*	*0*	*0*	*0*
Chemistry & Manufacturing	0	0	0	0	0
Backlog	*0*	*0*	*0*	*0*	*0*
Total	2	13	0	0	0
Non Backlog	2	13	0	0	0
BACKLOG	0	0	0	0	0
% in Backlog	0%	0%	0%	0%	0%

DECISIONS

DINB: Number of Decisions by Fee Category

DINB - LABELLING ONLY					
DOCUMENT TYPE	**Jan-Mar 2020**	**Apr-Jun 2020**	**Jul-Sep 2020**	**Oct-Dec 2020**	**Jan-Mar 2021**
DINB APPROVAL LETTER	0	3	0	11	1
SCREENING DEFICIENCY NOTICE	0	0	0	0	0
CANCELLED BY COMPANY	0	0	0	2	0
NOTICE OF DEFICIENCY	0	0	0	2	0

DINB - CLINICAL OR NON CLINICAL DATA AND C&M					
DOCUMENT TYPE	**Jan-Mar 2020**	**Apr-Jun 2020**	**Jul-Sep 2020**	**Oct-Dec 2020**	**Jan-Mar 2021**
SCREENING DEFICIENCY NOTICE	0	0	0	0	0
CANCELLED BY COMPANY	0	0	0	0	0

DINB - CHEMISTRY & MANUFACTURING					
DOCUMENT TYPE	**Jan-Mar 2020**	**Apr-Jun 2020**	**Jul-Sep 2020**	**Oct-Dec 2020**	**Jan-Mar 2021**
DINB APPROVAL LETTER	0	0	1	0	0
SCREENING DEFICIENCY NOTICE	0	0	0	0	0
NOTICE OF DEFICIENCY	0	0	0	0	0
NOTIFICATION FORM/DIN ISSUED	0	0	0	0	0
CANCELLED BY COMPANY	0	0	0	0	0

DINB - COMPARATIVE STUDIES					
DOCUMENT TYPE	**Jan-Mar 2020**	**Apr-Jun 2020**	**Jul-Sep 2020**	**Oct-Dec 2020**	**Jan-Mar 2021**
SCREENING DEFICIENCY NOTICE	0	0	0	0	0
REJECTION LETTER (SCR)	0	0	0	0	0

DINB - Administrative					
DOCUMENT TYPE	**Jan-Mar 2020**	**Apr-Jun 2020**	**Jul-Sep 2020**	**Oct-Dec 2020**	**Jan-Mar 2021**
DINB APPROVAL LETTER	0	0	1	0	2
CANCELLED BY COMPANY	0	0	0	0	0

PERFORMANCE

DINB: Review Cycle Completions



DINB: Screening Cycle Completions



POST-AUTHORIZATION DIVISION 1 CHANGE FOR A BIOLOGIC DRUG PRODUCT (PDC-B)

PDC-B: Number Received



YEARLY BIOLOGIC PRODUCT REPORTS (YBPR) [9]

YBPR: Number Received



[9] Yearly Biologic Product Report (YBPR) is a report that must be submitted annually by manufacturers of all Schedule D (Biologic) drugs. The report contains production information on both drug substance and drug product lots, including test methods and results, reasons for any recalls and corrective action taken, as well as other pertinent post-market information.

APPENDIX A: PRE-SUBMISSION MEETINGS [10]

Pre-submission Meetings Held / Feedback Provided



	MPNDS	MPSNDS	MPNC	PRECTA	MPDIN
JAN-MAR 2020	8	10	0	11	1
APR-JUN 2020	11	4	0	24	0
JUL-SEP 2020	10	9	0	16	1
OCT-DEC 2020	14	5	0	15	0
JAN-MAR 2021	9	6	0	11	0

[10] Prior to filing a submission, the sponsor may request a pre-submission meeting to discuss the presentation of data in support of the submission: For further information, refer to the Guidance for Industry: Management of Drug Submissions.